(Total Views: 553)
Posted On: 02/23/2017 9:35:13 AM
Post# of 111
RDHL-
Select 2016 milestones include:*
Successful final results from the first Phase III study with RHB-105 for
the treatment of _H. pylori_ infection
Positive and unanimous independent DSMB recommendation for the
continuation of the Phase III study with RHB-104 for Crohn's disease (the
MAP US study)
Encouraging top-line final results from the Phase IIa proof-of-concept
study with RHB-104 for relapsing-remitting multiple sclerosis
Exclusive U.S. co-promotion agreement with Concordia for
gastrointestinal drug Donnatal(R)
*Select potential milestones expected in 2017:*
Initiation of a confirmatory Phase III study with RHB-105 for the
treatment of _H. pylori_ infection, expected in Q2/2017
Second independent DSMB meeting for the MAP US Phase III study with
RHB-104 for Crohn's disease, including an interim efficacy analysis and an
evaluation of an option for early stop for success for overwhelming
efficacy, expected in Q2/2017
Top-line results from the BEKINDA(R) Phase III study for gastroenteritis
(the GUARD study), expected in Q2/2017
Top-line results from the BEKINDA(R) Phase II study for IBS-D, expected
mid-2017
Initiation of promotional activities for Donnatal(R) in selected U.S.
territories
Select 2016 milestones include:*
Successful final results from the first Phase III study with RHB-105 for
the treatment of _H. pylori_ infection
Positive and unanimous independent DSMB recommendation for the
continuation of the Phase III study with RHB-104 for Crohn's disease (the
MAP US study)
Encouraging top-line final results from the Phase IIa proof-of-concept
study with RHB-104 for relapsing-remitting multiple sclerosis
Exclusive U.S. co-promotion agreement with Concordia for
gastrointestinal drug Donnatal(R)
*Select potential milestones expected in 2017:*
Initiation of a confirmatory Phase III study with RHB-105 for the
treatment of _H. pylori_ infection, expected in Q2/2017
Second independent DSMB meeting for the MAP US Phase III study with
RHB-104 for Crohn's disease, including an interim efficacy analysis and an
evaluation of an option for early stop for success for overwhelming
efficacy, expected in Q2/2017
Top-line results from the BEKINDA(R) Phase III study for gastroenteritis
(the GUARD study), expected in Q2/2017
Top-line results from the BEKINDA(R) Phase II study for IBS-D, expected
mid-2017
Initiation of promotional activities for Donnatal(R) in selected U.S.
territories
(0)
(0)Scroll down for more posts ▼
